News | Radiopharmaceuticals and Tracers | November 05, 2022

The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions

The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions

Getty Images


Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical issues with the BR2 reactor in Belgium and possible Mo-99 supply disruptions through mid- to late-November. 

ASNC has connected with radiopharmaceutical manufacturers to assess their ability to meet the Mo-99 / Tc-99m needs of nuclear cardiology laboratories. Some suppliers have indicated they expect to be able to meet the needs of their regular customers and fulfill some additional demand. Other suppliers have warned that disruptions are likely. 

What Should You Do?

ASNC recommends nuclear cardiology laboratories take the following steps: 

1.    Confirm with your supplier if there will be an interruption in Tc-99m supply.

2.    If so, reschedule patients who are high priority to have their imaging test prior to the supply interruption.

3.    Reschedule less urgent patients to a later date after the Tc-99m supply is expected to be restored.

4.    If necessary, consider alternative testing options based on the principles of PatientFirst Imaging. 

ASNC will continue to monitor the situation. 

For more information: www.asnc.org

Related Radioisotope Content:   

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225) 

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)   

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal   

Update on Unplanned Outage of the HFR Reactor   

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply   

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals   

How Nuclear Fusion is Revolutionizing Medical Isotope Production   

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes   

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE   

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m


Related Content

News | Proton Therapy

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
News | RSNA

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
News | Radiopharmaceuticals and Tracers

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
News | PET Imaging

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
News | PET Imaging

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
News | SPECT-CT

October 18, 2022 — Spectrum Dynamics announced its newest development in digital nuclear medicine imaging: the ...

Time October 18, 2022
arrow
News | Quality Assurance (QA)

October 7, 2022 — Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and ...

Time October 07, 2022
arrow
News | Radiopharmaceuticals and Tracers

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
Subscribe Now